MedTech M&A: 213 Deals and a Clear Flight to Specialists

MedTech M&A 2026 entered on strong footing and stayed active through the first half, with 213 transactions recorded across the segments we track. The pace built on the decade-high volumes of 2025, but buyers were visibly more selective: capital concentrated in category leaders, proprietary technology, resilient manufacturing platforms, and access to attractive geographies. Despite tariff and geopolitical uncertainty, together with ongoing reimbursement pressure, strategics and sponsors stayed in the market for differentiated, revenue-generating assets.

At MP Corporate Finance, we track developments across medical OEMs and component manufacturing and read the market through three lenses that actually drive buyer behaviour: position in the value chain (OEM, specialist device maker, CDMO & precision component), end-market modality (cardiovascular, structural heart, neurovascular, orthopaedics & robotics, patient monitoring & connected care, diagnostics, drug-delivery adjacent, hearing), and buyer archetype (large strategic consolidator, mid-cap strategic extending capability, PE platform). The first half of MedTech M&A 2026 highlighted a clear investment priority: acquisitions that add specialist capabilities, strengthen OEM relationships and secure defensible positions in regulated end-markets.

CDMO consolidation sets the structural tone

The single most important structural story of the first half of MedTech M&A 2026 is the consolidation of CDMOs and precision component manufacturers. Tecomet–Orchid is the anchor transaction; Resonetics / Resolution Medical illustrates the same thesis one tier down; IGS / ACH Solution is the PE-backed drug-delivery-tooling expression of it. OEM supplier rationalisation is pulling value toward integrated providers with multi-regional footprints and real regulatory muscle, and both strategics and sponsors are underwriting that shift.

Strategic buyers and private equity reshape portfolios

Strategic acquirers continued to lead deal volume, while private-equity sponsors and PE-backed platforms accounted for a meaningful and rising share of activity. Large OEMs used M&A to reshape portfolios around higher-growth categories like cardiovascular, structural heart, neurovascular, patient monitoring, diagnostics and connected care, while sponsors concentrated on specialized manufacturing, CDMO platforms and capability-driven bolt-ons.

North American companies remained the most active acquirers, Europe continued to supply the specialist targets, and Asia-Pacific countries like India, Japan and Singapore in particular gained weight both as a source of capital and as an emerging buyer base. The transactions span new platform investments, bolt-ons that expand existing portfolios, and funding rounds supporting clinical development and commercialisation.

A few deals capture the pattern. Danaher’s acquisition of Masimo built out patient monitoring and diagnostics. Boston Scientific’s acquisition of Penumbra strengthened thrombectomy and vascular. Medtronic acquired SPR Therapeutics in non-opioid pain management and Scientia Vascular in neurovascular. In Europe, Amplifon and GN Hearing combined to create an integrated hearing platform, Arthrex acquired Corin Group in joint replacement and robotics, and Ottobock extended its patient-care network into Norway through Blatchford.

On the sponsor side, AIP acquired Avanos Medical, G Square Healthcare and ValBlue acquired Valtecne, and IGS extended its drug-delivery tooling platform into LSR tooling through ACH Solution. Kimball Solutions’ acquisition of Helvoet Polymer is a different expression of the same thesis — an EMS player integrating high-precision medical moulding and microfluidics knowledge, and a polymer group accelerating its MedTech position through a focused new owner.

Valuations reflect differences across the sector

Listed peer-group valuations show meaningful variation across the segments. Year-on-year, multiples compressed in every segment as valuations normalised from post-pandemic highs toward long-term averages.

Operating profitability varied as expected along the value chain. Median EBITDA margins reached 25.8% for medical OEMs, 18.2% for polymer components, 16.9% for electronics and 16.3% for metal components. OEMs continue to earn the highest margins and the most consistent cash conversion; component peers trade on tighter margins but, in the specialist tier, on comparable multiples.

Large, diversified OEMs anchor the market at a median c.10x TEV/EBITDA with 25.8% EBITDA margins and the strongest cash conversion. CDMOs and precision component manufacturers trade in the high single digits to low teens, with multiples that reflect OEM concentration, regulatory maturity and manufacturing footprint. Cutting across all peer groups is a clear specialist-premium tier: Johnson & Johnson (18.7x), Danaher (18.0x), Abbott (15.3x), West Pharmaceutical (27.2x, biologics drug delivery), Teleflex (16.7x, specialist interventional and vascular access) and Globus Medical (10.3x, spine and robotics) trade well above their peer medians because they sit in regulated, proprietary or technically differentiated positions.

These benchmarks provide context, not acquisition multiples. Individual transaction valuations depend on quality of earnings, OEM concentration, regulatory position, technical differentiation and strategic value to a specific buyer.

Deep dive 1: CDMOs and precision manufacturing

H1 MedTech M&A 2026 confirmed CDMOs as the pivotal arena. Tecomet–Orchid created a broader global manufacturing platform; Resonetics’ acquisition of Resolution Medical scaled medical-device design and manufacturing; and IGS’s acquisition of ACH Solution brought medical LSR capabilities into a PE-backed drug-delivery-tooling platform. Kimball Solutions / Helvoet Polymer sits in the same arena from the adjacent-platform angle, with an EMS player bringing medical polymer moulding and microfluidics capability in-house to serve its MedTech customers end-to-end. The investment themes carrying diligence are consistent across buyers: automation, AI-enabled operations, regulatory readiness (EU MDR/IVDR, FDA cycle times), supply-chain resilience and integrated end-to-end services. OEM supplier consolidation is doing the rest of the work.

Deep dive 2: modality-led strategic consolidation

Across devices, strategics continued to reshape portfolios around specific modalities. In cardiovascular and structural heart, Boston Scientific acquired MiRus; Alkem added Occlutech; and Lifetech acquired Starway. In neurovascular, Boston Scientific acquired Penumbra and Medtronic added Scientia Vascular. In orthopaedics and robotics, Arthrex acquired Corin Group; in soft-tissue and sports medicine, Smith & Nephew added Integrity Orthopaedics.

In surgical instruments, Gilde Healthcare’s buy-and-build platform continued to scale across European specialist manufacturers, illustrating sponsor appetite for fragmented, high-mix regulated niches where consolidation can create a defensible European champion. In patient monitoring and diagnostics, Danaher acquired Masimo and Agilent added Biocare Medical. In hearing and connected care, Amplifon and GN Hearing combined. In sleep and neuromodulation, ResMed added Noctrix Health in restless legs therapy, and Medtronic acquired SPR Therapeutics in non-opioid pain management. The common thread is category leadership and defensible OEM / clinical positioning.

MedTech component and OEM businesses remain attractive targets due to their resilient revenues, stable EBITDA margins and improving balance-sheet positions — a combination that continues to appeal to both strategic and financial buyers.

MedTech M&A 2026 outlook: selectivity, specialisation and disciplined underwriting

We expect MedTech M&A 2026 to remain healthy through the second half as strategics continue to reshape portfolios and sponsors continue to build platforms around specialised manufacturing and connected-care technologies. Improving financing conditions and strong corporate balance sheets support activity, but tariffs, reimbursement pressure, regulatory complexity and integration risk will sustain disciplined underwriting.

Two structural factors warrant close attention. Supply-chain resilience and reshoring are reshaping how OEMs think about their component base, pulling value toward integrated CDMOs with multi-regional operations and robust quality systems. Regulatory readiness (EU MDR/IVDR execution, FDA cycle times and quality-system maturity) is now a first-order diligence item, not a footnote. Neither factor applies evenly, but both are visible in current deal theses and should shape how a transaction is prepared.

For business owners and acquirers, the question is how proprietary technology, specialist manufacturing capability and defensible OEM relationships can be positioned to strengthen competitiveness and support future growth.

For owners considering their strategic options, demonstrating those strengths is essential. Sustainable margins, blue-chip OEM relationships, regulatory maturity and a defensible technical position help establish a clear investment case. In a selective market, predictable earnings and operational resilience carry particular weight.

If you would like to discuss what the current MedTech M&A environment means for your business, we would be happy to share our perspective. Get in touch and explore opportunities with us!